Maravai LifeSciences Announces Executive & Board Changes

TL;DR

CFO out, CSO in, 2 new directors join Maravai's board.

AI Summary

Maravai LifeSciences Holdings, Inc. announced on December 3, 2024, the departure of its Chief Financial Officer, William R. Floyd. The company also announced the appointment of Dr. Adina Kalush as Chief Scientific Officer and the election of two new directors, Dr. David R. Walt and Dr. Paul J. Bolger, to its Board of Directors. These changes are effective immediately.

Why It Matters

Significant leadership and board changes can signal strategic shifts or reflect responses to performance, potentially impacting investor confidence and future company direction.

Risk Assessment

Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding strategy and execution.

Key Players & Entities

• Maravai LifeSciences Holdings, Inc. (company) — Registrant
• William R. Floyd (person) — Departing Chief Financial Officer
• Dr. Adina Kalush (person) — Appointed Chief Scientific Officer
• Dr. David R. Walt (person) — Elected Director
• Dr. Paul J. Bolger (person) — Elected Director
• December 3, 2024 (date) — Effective date of changes

FAQ

Key Financial Figures

• $0.01 — which registered Class A Common Stock, $0.01 par value MRVI The Nasdaq Stock Market
• $175,000 — e to receive an annual cash retainer of $175,000, commencing January 1, 2025, which reta
• $750,000 — U award with a grant date fair value of $750,000 (based on the closing price of the Comp
• $500,000 — ng Date with a grant date fair value of $500,000 (based on the closing price of the Comp

Filing Documents

• mrvi-20241203.htm (8-K) — 39KB
• ex101-mrvirsuagmt2024rsuae.htm (EX-10.1) — 42KB
• ex102-mrvirsuagmt2025rsuae.htm (EX-10.2) — 40KB
• ex991mrvipr-bodchairtransi.htm (EX-99.1) — 11KB
• image_0.jpg (GRAPHIC) — 3KB
• 0001823239-24-000124.txt ( ) — 284KB
• mrvi-20241203.xsd (EX-101.SCH) — 2KB
• mrvi-20241203_lab.xml (EX-101.LAB) — 22KB
• mrvi-20241203_pre.xml (EX-101.PRE) — 13KB
• mrvi-20241203_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. A copy of the press release announcing the appointment of Mr. Eckert as Chairman of the Board is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished as part of this Current Report on Form 8-K: Exhibit No. Description of Exhibit 10.1 Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (2024 RSU Award). 10.2 Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (2025 RSU Award). 99.1* Press Release dated December 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) _______________ * Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARAVAI LIFESCIENCES HOLDINGS, INC. Date: December 5, 2024 By: /s/ Kevin M. Herde Name: Kevin M. Herde Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR